Lovastatin for the Treatment of Adult Patients with Dengue: A Randomized, Double-Blind, Placebo-Controlled Trial

Clinical Infectious Diseases

Volumn 62, Issue 4, 2015, Pages 468-476

  Whitehorn, James ^a,b   Nguyen, Chau Van Vinh ^c   Khanh, Lam Phung ^b   Kien, Duong Thi Hue ^b   Quyen, Nguyen Than Ha ^b   Tran, Nguyen Thi Thanh ^b   Hang, Nguyen Thuy ^b   Truong, Nguyen Thanh ^c   Hue Tai, Luong Thi ^c   Cam Huong, Nguyen Thi ^c   Nhon, Vo Thanh ^d   Van Tram, Ta ^d   Farrar, Jeremy ^b,e   Wolbers, Marcel ^b,e   Simmons, Cameron P ^b,e,f   Wills, Bridget ^b,e  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d Tien Giang Hospital   (Viet Nam)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

dengue; lovastatin; randomized clinical trial

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; MEVINOLIN; PLACEBO; SODIUM; ANTIINFLAMMATORY AGENT;

ABDOMINAL PAIN; ADULT; ARTICLE; BLEEDING; CONTROLLED STUDY; DENGUE; DIARRHEA; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; FEVER; GINGIVA BLEEDING; HEPATITIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MYALGIA; MYOSITIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; VAGINA BLEEDING; VIETNAMESE; VIREMIA; VOMITING; ADVERSE DRUG REACTION; PATHOLOGY; VIET NAM; YOUNG ADULT;

ADULT; ANTI-INFLAMMATORY AGENTS; DENGUE; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; LOVASTATIN; MALE; PLACEBOS; TREATMENT OUTCOME; VIETNAM; YOUNG ADULT;

EID: 84959417333     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ949     Document Type: Article

References (30)

1. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature 2013; 496:504-7.
2. Simmons CP, Farrar JJ, Nguyen VV, Wills B. Dengue. N Engl J Med 2012; 366:1423-32.
3. Wijesinghe A, Gnanapragash N, Ranasinghe G, Ragunathan MK. Acute renal failure due to rhabdomyolysis following dengue viral infection: a case report. J Med Case Reports 2013; 7:195.
4. Ii M, Losordo DW. Statins and the endothelium. Vascul Pharmacol 2007; 46:1-9.
5. Tong XK, Hamel E. Simvastatin restored vascular reactivity, endothelial function and reduced string vessel pathology in a mouse model of cerebrovascular disease. J Cereb Blood Flow Metab 2015; 35:512-20.
6. Tousoulis D, Psarros C, Demosthenous M, Patel R, Antoniades C, Stefanadis C. Innate and adaptive inflammation as a therapeutic target in vascular disease: the emerging role of statins. J Am Coll Cardiol 2014; 63:2491-502.
7. Antoniades C, Bakogiannis C, Leeson P, et al. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circulation 2011; 124:335-45.
8. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-78.
9. Schmidt H, Hennen R, Keller A, et al. Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome. Intensive Care Med 2006; 32:1248-51.
10. Kruger P, Fitzsimmons K, Cook D, Jones M, Nimmo G. Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med 2006; 32:75-9.
11. Mortensen EM, Restrepo MI, Anzueto A, Pugh J. The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res 2005; 6:82.
12. Kruger P, Bailey M, Bellomo R, et al. A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis. Am J Respir Crit Care Med 2013; 187:743-50.
13. McAuley DF, Laffey JG, O'Kane CM, et al. Simvastatin in the acute respiratory distress syndrome. N Engl J Med 2014; 371:1695-703.
14. Martinez-Gutierrez M, Castellanos JE, Gallego-Gomez JC. Statins reduce dengue virus production via decreased virion assembly. Intervirology 2011; 54:202-16.
15. Rothwell C, Lebreton A, Young Ng C, et al. Cholesterol biosynthesis modulation regulates dengue viral replication. Virology 2009; 389:8-19.
16. Martinez-Gutierrez M, Correa-Londono LA, Castellanos JE, Gallego-Gomez JC, Osorio JE. Lovastatin delays infection and increases survival rates in AG129 mice infected with dengue virus serotype 2. PLoS One 2014; 9:e87412.
17. Desai CS, Martin SS, Blumenthal RS. Non-cardiovascular effects associated with statins. BMJ 2014; 349:g3743.
18. Russo MW, Hoofnagle JH, Gu J, et al. Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology 2014; 60:679-86.
19. Whitehorn J, Van Vinh Chau N, Truong NT, et al. Lovastatin for adult patients with dengue: protocol for a randomised controlled trial. Trials 2012; 13:203.
20. Hue KD, Tuan TV, Thi HT, et al. Validation of an internally controlled one-step real-time multiplex RT-PCR assay for the detection and quantitation of dengue virus RNA in plasma. J Virol Methods 2011; 177:168-73.
21. Tam DT, Ngoc TV, Tien NT, et al. Effects of short-course oral corticosteroid therapy in early dengue infection in Vietnamese patients: a randomized, placebo-controlled trial. Clin Infect Dis 2012; 55:1216-24.
22. Rothwell PM. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet 2005; 365:176-86.
23. Trung DT, Thao le TT, Dung NM, et al. Clinical features of dengue in a large Vietnamese cohort: intrinsically lower platelet counts and greater risk for bleeding in adults than children. PLoS Negl Trop Dis 2012; 6:e1679.
24. Tricou V, Minh NN, Van TP, et al. A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults. PLoS Negl Trop Dis 2010; 4: e785.
25. Nguyen NM, Tran CN, Phung LK, et al. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J Infect Dis 2013; 207:1442-50.
26. Low JG, Sung C, Wijaya L, et al. Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebocontrolled, proof-of-concept trial. Lancet Infect Dis 2014; 14:706-15.
27. Libraty DH, Endy TP, Houng HS, et al. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis 2002; 185:1213-21.
28. Yacoub S, Wills B. Predicting outcome from dengue. BMC Med 2014; 12:147.
29. Whitehorn J, Van VC, Simmons CP. Dengue human infection models supporting drug development. J Infect Dis 2014; 209(suppl 2):S66-70.
30. Criner GJ, Connett JE, Aaron SD, et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med 2014; 370:2201-10.